The present invention discloses an enzymatic method for preparing glutathione (GSH), comprising the following steps: (1) producing glutathione in a reactor using GshF enzyme, ATP regeneration enzyme and AK enzyme; (2) separating immobilized GshF enzyme, ATP regeneration enzyme and AK enzyme in the reactor, or separating free GshF enzyme using a filtration device; (3) separating the filtrate obtained in step (2) to obtain a crude product GSH and a small amount of ATP, ADP and AMP; and (4) subjecting the GSH obtained in step (3) to concentration, crystallization, and drying to prepare a finished GSH. The disclosed method provides: greatly reduced industrial production costs; faster reaction rate; stable enzyme recovery system that is energy efficient and environmentally friendly; and capability of reusing the byproducts or collecting them for the production of ATP.

The invention provides sulfoxyalkyl organonitro and related compounds, compositions containing such compounds, and methods for using such compounds and compositions to treat medical disorders, such as a neurodegenerative disorder, autoimmune disease, infection, or cancer in a patient. Exemplary sulfoxyalkyl organonitro compounds described herein include ((2-(3,3-dinitroaze-tidin-1-yl)-2-oxoethyl)sulfinyl)-D-alanine and variants thereof.

The present invention provides a crystal of reduced glutathione that is stable, and is easy to process, and a method for producing the crystal. According to the present invention, a crystal of a metal salt of reduced glutathione is produced by suspending an amorphous solid of a metal salt of reduced glutathione in a hydrophobic organic solvent, and adding water to the resulting suspension to precipitate a crystal of a metal salt of reduced glutathione.

The present application discloses a crystal of oxidized glutathione dication salt and a method of producing the same.

An enzyme-responsive peptide and a method off using such enzyme-responsive peptide are disclosed. An enzyme-responsive peptide, the peptide comprising an amino acid having an -amino group, an -carboxylic acid group and a -amine group, wherein the -amine group is covalently bonded with a first group and the -carboxylic acid is covalently bonded with a second group.

The present invention relates to a crystal of glutathione trisulfide dihydrate and a method for producing the same. According to the present invention, for example, the crystal can be provided by concentrating an aqueous solution in which glutathione trisulfide is dissolved and collecting the precipitated crystal of glutathione trisulfide dihydrate. In addition, the present invention relates to a simple method for producing polysulfide in an aqueous solvent using thiosulfate without using hydrogen sulfide, by stirring an aqueous solution in which a compound having a thiol group or a disulfide bond and thiosulfate are dissolved or by leaving the aqueous solution to stand.

The present invention relates to a compound simultaneously having triple activities of thrombolysis, antithrombosis and free radical scavenging, as well as the preparation method, composition, and applications thereof. The compound is represented by the formula I shown below:

##STR00001##

wherein the definitions of T, Q, R.sub.1 and R.sub.2 are described herein. The compound of the present invention simultaneously has triple functions of thrombolysis, free radical scavenging and thrombus-targeting/antithrombosis. The present invention also relates to a pharmaceutical composition comprising the compound, and a preparation method and a nanostructure of the compound.

The present invention describes compositions containing cholesterol-linker-glutathione conjugates for targeting the brain by overcoming barrier entry to the CNS through the blood brain barrier (BBB), including micelle and liposome forms of such compositions. In addition, methods for treating subjects by administering such compositions are also disclosed.

Prodrugs of galiellactone, and derivatives thereof, are provided by reacting the parent compound, e.g. galiellactone, with a thiol. Such drugs may be administered orally to treat cancer and other proliferative diseases.

Methods, systems, and devices are disclosed for in vivo production or biosynthesis of metabolites in foreign cells using the combination of (i) one or more ferredoxin dependent enzyme(s) and (ii) a ferredoxin (Fd)/ferredoxin-NADP.sup.+ reductase (FNR) system. The ferredoxin dependent enzymes and the Fd/FNR system are from the same species or from a different but matching species.